Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596859 | 1.00 | CHRM4 (0.37) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL22795652 | 0.89 | CHRNB4 (0.38) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL12524364 | 0.87 | CHRM4 (0.39) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL22795905 | 0.83 | CNR2 (0.39) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL22795641 | 0.81 | SMPD3 (0.39) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL25812286 | 0.78 | SMPD3 (0.37) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL29597502 | 0.78 | CHRM4 (0.39) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL24623312 | 0.78 | CHRM4 (0.39) | CHRM4CHRM2PANK3CHRNB4CHRNA3 | |
| SCHEMBL3608762 | 0.77 | SMO (0.47) | PANK3CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20070056 | 0.76 | SMPD3 (0.44) | PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | RET, BRAF, ROR1 | CHRM4 4838/4885CHRM2 4859/4885PANK3 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.